This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nielsen, O. W. Articles by Dargie, H. J. Search for Related Content PubMed PubMed Citation Articles by Nielsen, O. W. Articles by Dargie, H. J.

Retrospective analysis of thecost-effectiveness of using plasmabrain natriuretic peptide inscreening for left ventricularsystolic dysfunction in the general population

Olav W. Nielsen, MD, PhD^*,*, Theresa A. McDonagh, BSc, MB, ChB, MD, FRCP, Stephen D. Robb, MB, ChB, MD, MRCP and Henry J. Dargie, MB, ChB, FRCP, FESC

^* Cardiology Department, The Western Infirmary, Glasgow and Clinical Research Initiative in Heart Failure, University of Glasgow, Glasgow, United Kingdom
Cardiology Department, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark

View larger version (23K): [in a new window]   Figure 1 Histogram showing the distribution of plasma brain natriuretic peptide (BNP) in subjects with left ventricular systolic function (LVSD) (solid bars, right y-axis) and without LVSD (open bars, left y-axis). The x axis is logarithmically scaled to approach normality. The interval 1–2 means 1.0 and 2.0; the interval 2 to 4 means >2.0 and 4.0, etc. The y axis contains the number of subjects with a plasma value within the specified interval. EF = ejection fraction.